MGN1703

MGN1703 · Mologen AG

Drug timelines are a Plus or Pro feature.

5 regulatory and trial events tracked for MGN1703, covering 2014-05-19 to 2026-04-07. Get the full timeline:

Most recent: Clinical Trial Update: Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies [Phase 1]